a:5:{s:8:"template";s:1952:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>{{ keyword }}</title>
</head>
<style rel="stylesheet" type="text/css">@charset "UTF-8";a,body,div,h1,h2,html{border:0;font-family:inherit;font-size:100%;font-style:inherit;font-weight:inherit;margin:0;outline:0;padding:0;vertical-align:baseline;word-break:break-word}html{font-size:62.5%;overflow-y:scroll;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}*{-webkit-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;box-sizing:border-box}body{background:#fff}article,header,main{display:block}a:active,a:focus,a:hover{outline:0}body{color:#333;font-family:Montserrat,sans-serif;font-size:14px;line-height:1.5;font-weight:400;text-rendering:optimizeLegibility;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}h1{font-size:36px}h2{font-size:30px}h1,h2{font-weight:700}hr{background-color:#ccc;border:0;height:1px;margin-bottom:15px}a{color:#000;text-decoration:none;transition:all .3s ease-in-out;-webkit-transition:all .3s ease-in-out;-moz-transition:all .3s ease-in-out}a:hover{color:#000}#primary{float:left;width:65.5%}.post{margin-bottom:40px;display:inline-block}.entry-meta{font-size:12px;margin-top:12px}.blog .entry-content-block{width:100%}.entry-content-block .entry-title{font-size:18px}.post{width:100%}.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}.has-drop-cap:not(:focus):after{content:"";display:table;clear:both;padding-top:14px}</style>
<body class="">
<div id="page">
<div id="header" role="banner">
<div id="headerimg">
<h1><a href="#">{{ keyword }}</a></h1>
</div>
</div>
<hr/>
{{ text }}
<br>
<br>
{{ links }}
<hr/>
<div id="footer" role="contentinfo">
<p>
{{ keyword }} 2021</p>
</div>
</div>
</body>
</html>";s:4:"text";s:25447:"Editas Medicine Inc. (EDIT) estimates and forecasts Editas Medicine Inc. share prices are performing particularly well not compared to other companies within the same industry. The best health care stocks to buy for 2021Health care stocks failed to keep up with the broader market last year, advancing 11% while the S&P 500 as a whole rose 15. Editas Medicine last announced its earnings results on May 5th, 2021. How has Editas Medicine's share price performed over time and what events caused price changes? Editas Medicine Inc. [NASDAQ: EDIT] price plunged by -8.90 percent to reach at -$3.43. DVA was an outstanding performer in 2020, rising 55%. Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth GlobeNewswire. EDIT has risen $8.15 from the previous closing price of $43.18 on volume of 3,995,771 shares. Based on 11 analysts offering 12 month price targets for Editas Medicine in the last 3 months. Shares Outstanding. Over the next 52 weeks, Editas Medicine Inc has on average historically risen by 21 % based on the past 5 years of stock performance. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment have been in a bullish cycle in the last â¦ 07:14 AM ET. Editas Medicine. ... they have bought $0.00 in company stock and sold $2,005,327.00 in company stock. Editas Medicine is listed on the NASDAQ and employs 235 staff. The company recorded a loss per share of 1.98.Editas Medicine had not issued any dividends in recent years. Based on data from June 07, 2021 at 03:56, the general Editas Medicine, Inc. price prediction sentiment is bearish, with 6 technical analysis indicators signaling bullish signals, and 20 signaling bearish signals.. Editas Medicine, Inc. price prediction was last updated on June 07, 2021 â¦ Sumitomo Mitsui Trust Holdings Inc. owned about 0.06% of Editas Medicine worth $177,358,000 as of its [â¦] The move came on solid volume too with far more shares changing hands than in a normal session. The fund owned 4,222,802 shares of the companyâs stock after selling 165,341 shares during the quarter. Editas Medicine Inc (EDIT) stock has risen 18.87% while the S&P 500 is down -0.42% as of 1:11 PM on Wednesday, Dec 9. The business had revenue of $6.50 million for the quarter, compared to analysts' expectations of $5.78 million. Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. EDIT Dip Buy. Editas Medicine announced its fourth-quarter and full-year 2017 results this month. This price target is based on 12 analysts offering 12 month price targets for Editas Medicine in the last 3 months. Trading is expected to begin on a stock split-adjusted basis on July 20. Editas Medicine, Inc. provides genetic engineering services. Cons. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Its shares traded higher over the last trading ses ET to provide and discuss a corporate update and financial results for the first quarter 2021. The average price target represents a 32.08% upside from the last price of $35.86. Editas Medicine stock ("EDIT" on the Nasdaq Exchange) was up 50.85 percent in just three hours. Biotech Bonanza: 2021 Outlook In A Post-Pandemic Year. Volume reflects consolidated markets. Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 3.8% during the 1st quarter, HoldingsChannel reports. Editas Medicine -2.3% AH, announces stock offering seekingalpha.com Jan 20, 2021 5:10 am Editas Medicine falls -6.5% with a downgrade to Underweight by Morgan Stanley analyst, PT of $45 The 11 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 40.00, with a high estimate of 81.00 and a low estimate of 20.00. Editas Stock Set to Fly Higher on this Technology One of our strategies for investing in high-growth stocks is to look for companies with cutting-edge technologies in emerging fields. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine Gene editing has emerged as a promising biotech theme. Stock Market Predictions. The dayâs price range saw the stock hit a low of $75.05, while the highest price level was $88.00. Pipeline development remains in focus for the company. To hit the forecast high, the stockâs price needs a -3.62% upsurge from its current level, while the stock would need to tank -80.44% for it to hit the projected low. On Monday, shares of Editas Medicine (NASDAQ: EDIT) saw unusual options activity. Editas Medicine Inc. [NASDAQ: EDIT] closed the trading session at $76.94 on 01/11/21. About the Tesla, Inc. stock forecast. Zacks Equity Research - ZACKS - Wed May 5, 10:05AM CDT. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 82 cents per share.The â¦ Notably, Editas has a â¦ Editas Medicine Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. So take a peek at this free list of growing companies with insider buying. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered by Barchart Solutions. Revenue growth over the past 12 months for Editas Medicine Inc comes in at 278.37%, a number that bests 97.36% of the US stocks we're tracking. The EDIT stockâs 52-week price range has touched low of $24.98 and a $99.95 high. At the same time, the Dow lost 0.12%, and the tech-heavy Nasdaq gained 0.69%. CRISPR () (clustered regularly interspaced short palindromic repeats) is a family of DNA sequences found within the genomes of prokaryotic organisms such as bacteria and archaea. Are you long Activision Blizzard stock? Editas Medicine Inc Stock Forecast. 10 Best Pharmaceutical Stocks to Buy According to Cathie Wood. The question becomes, what are the chances the stock â¦ Per-share losses are expected to explode, reaching US$3.29 per share. Since the market opened on Dec. 22, the stock has â¦ Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Jun 11, ... Editas stock is trading at 49x its expected RPS of $1.48, which appears â¦ Robert W. Baird initiated coverage on Editas Medicine in a research [â¦] Editas Medicine earnings estimates module stress-tests analyst consensus about projected Editas Medicine EPS (Earning Per Share) to derive its highest and lowest estimates based on its â¦ During the day the price has varied from a low of $47.1501 to a high of $48.82. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. Goldman Sachs projects GDP will grow at a 5.3% pace in 2021 and forecasts a lower unemployment rate at 5.3%. They expect the S&P to rise 17% to 4,300 points, and driven by an expected 30% growth in corporate earnings. Morgan Stanley, Wells Fargo and LPL Financial see the S&P rising 6% to reach 3,900. Oppenheimer boldly sees it hitting 4300. For Editas Medicine stock forecast 2022, 12 predictions are offered for each month of 2022 with average Editas Medicine stock forecast of $46.64, a high forecast of $48.94, and a low forecast â¦ Since then, EDIT stock surged by 270.72%, with an average of 54.14% per year. We expect investors to focus on Editas Medicine, Inc.âs EDIT progress with its CRISPR-based experimental candidate EDIT-101 and other pipeline candidates when it reports first-quarter 2021 earnings results.. Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Editas Stock Set to Fly Higher on this Technology One of our strategies for investing in high-growth stocks is to look for companies with cutting-edge technologies in emerging fields. April 16, 2021. The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. The current Editas Medicine Inc [ EDIT] share price is $37.42. The average Editas Medicine stock forecast 2021 represents a 10.93% increase from the last price of $37.42. Editas: Q1 Earnings Snapshot. The latest price was $47.965 (25 minute delay). ... Editas Medicine May 21, 2021 - Senior Research Associate ... People genuinely care about their work, generous stock offerings, good work-life balance and management (Strongly depends on manager and department), interesting science. Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report To read this article on Zacks.com click here. Stock Price Forecast. PHOENIX, June 08, 2021 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) today reported Mesa Airlinesâ operating performance for May 2021. US Stocks Deer_Co, Docusign, Editas Medicine, Elbit Systems, Evogene, Faro Tech, Fate Therapeutics, Elliott Wave [Video] ANALYSIS | 10/11/2020 10:32:50 PM GMT Mesa Airlines reported 28,264 block hours in May 2021, a 134.0 percent increase from May 2020 as a result of increased flying due to industry recovery from the COVID-19 pandemic. Joe Biden's big tax increase along with inflation is sending the market plunging and the effect is chilling. At that level they are trading at 21.84% discount to the analyst consensus target price of 0.00. Editas Medicine share price volatility. This one loves holding Fibs so if we see someone support at this 38 that would be a solid entry. Editas Medicine Inc. NASDAQ Updated Jun 15, 2021 11:47 PM EDIT 35.10 3.43 (8.90%). EDIT lost -$1.72 per share the over the last 12 months. These stocks are even more popular and have stronger recommendations from our partners UXIN 68.38% UTHR 14.99% AMTI 44.44% LPRO 16.54% NBW 4.00% * data: BATS Data as of 2021-05-22 12:52:39 -0400. Editas Medicine last announced its earnings results on May 5th, 2021. January to provide further insights on multiple additional vaccine trials. If EDIT-101 works, the consensus is that it â¦ CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine â Forbes. 2.253 Billion. This change lagged the S&P 500's daily gain of 0.36%. , and has now gained 8 days in a row.It is not often that stocks manage to gain so many days in a row, and falls for a day or two should be expected. Post-Market 0.45 (1.28%) How has Editas Medicine's share price performed over time and what events caused price changes? The question becomes, what are the chances the stock â¦ But shares of Editas were â¦ If you had invested in Editas Medicine stock at $18.20, your return over the last 5 years would have been 105.6%, for an annualized return of 15.51%. Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. EDIT News. CAMBRIDGE, MA 02141. Editas Stock Forecast Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. The company report on January 11, 2021 that Editas Medicine Reports on Recent Progress and Outlook â¦ Editas Medicine operates in the United States. Forecast for Wed 28 Jul 2021 price 36.02 EDITAS MEDICINE INC stock price forecast for further price development down to -0.31% (time horizon: 1 â¦ As a group, analysts forecast that Editas Medicine will post -1.78 EPS for the current fiscal year. Editas Medicine (EDIT Quick Quote EDIT - Free Report) closed at $65.47 in the latest trading session, marking a -0.44% move from the prior day.This change lagged the S&P 500's daily gain of â¦ CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. If you had invested thousand dollars in Editas Medicine stock on the IPO, it would be valued $3,707.22 today. NasdaqGS:EDIT Insider Trading Volume April 15th 2021 Editas Medicine is not the only stock insiders are buying. Let our SmartScan and Trade Triangle technology, brought to you courtesy of our premium service MarketClub, instantly rank today's top 50 stocks for you.This complimentary list will update throughout the day to â¦ ... Editas Stock Forecast. Shares in Editas Medicine Inc are currently priced at $45. Editas Medicine has confirmed that its next quarterly earnings report will be published on Wednesday, May 5th, 2021. Editas Medicine will be holding an earnings conference call on Wednesday, May 5th. Hedge funds have recently made changes to their positions in the stock. Editas Medicine (EDIT) closed at $65.47 in the latest trading session, marking a -0.44% move from the prior day. If EDIT-101 works, the consensus is that it â¦ Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.75 with sales reaching $5.78M over the same period.The EPS is expected to grow by 26.00% this year, but quarterly earnings will post  â¦ Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Stock Predictons by days: 2021 Search Stock, FX pair, Crypto, or Commodity... Editas Medicine Inc Stock Forecast and Price Prognosis Data for 2021 Editas Medicine Inc. (NASDAQ: EDIT) is -41.55% lower on its value in year-to-date trading and has touched a low of $21.41 and a high of $99.95 in the current 52-week trading range. With a price/sales ratio of 26.02, Editas Medicine Inc has a higher such ratio than 91.65% of stocks in our set. Overall. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase... | June 3, 2021 Analysts covering Editas Medicine Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.378 for the next financial year. 9 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" Editas Medicine stock ("EDIT" on the Nasdaq Exchange) was up 50.85 percent in just three hours. Check out our latest analysis for Editas Medicine . Ended 2020 with strong cash position of $512 million, and raised additional $250 million in early 2021. April 16, 2021. EDIT.US volatility (beta: 1.93) Avg. Editas Medicine Inc. [NASDAQ: EDIT] price plunged by -8.90 percent to reach at -$3.43. Even though the sector has arguably been the most important of the 11 sectors to global well-being amid the pandemic, that trend continued in the first quarter of 2021, with health care stocks rising just 3. Editas Medicine is projected to generate -3.6729 in earnings per share on 31st of December 2021. May 5, 2021 Updated: May 5, 2021 4:16 a.m. CAMBRIDGE, Mass. Today's Top 50 Trending Stocks. Editas Medicine, Inc.(NASDAQ:EDIT): Fueled by the push to develop new gene therapies and vaccines to fight diseases, genomic stocks have generated decent momentum this year. It opened the day at $48.15 after a previous close of $46.66. Stocks: 15 20 minute delay (Cboe BZX is real-time), ET.  Editas Medicine, Inc ... looking at a company's recent surprise history can be a great aid in forecasting the surprise likelihood of their next outing. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. Is Editas Medicine Inc Stock Undervalued? Editas Medicine Inc. (NASDAQ:EDIT) has a beta of 1.95. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. NasdaqGS:EDIT Earnings and Revenue Growth January 21st 2021. Editas Medicine, Inc (EDIT) is a leading biotechnology business based in the US. This is 0.93% more than the trading day before Thursday, 3rd Jun 2021. JPMorgan Chase & Co. reaffirmed their sell rating on shares of Editas Medicine (NASDAQ:EDIT) in a research report report published on Sunday morning, AnalystRatings.com reports. FEB 25, 2021 - CAMBRIDGE, Mass. Editas Medicine went public priced at an adjusted price 1 of $18.00 on Feb 2016. The technology is used to insert, edit, or delete a gene from an organismâs genome, helping to replace the defective genes responsible for a medical condition with healthy versions. Pros. The 7 Best Long Term Stocks to Buy in 2021 Stock Market for Beginners: An Overview Best Stock Trading Apps Let's stop the grind, together. Jun 11, 2021, 03:38pm EDT. Norges Bank bought a new position in Editas Medicine during the 4th quarter valued at about $47,163,000. ... Editas Stock Forecast Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. Offering of Common Stock Strengthened balance sheet with net proceeds of approximately $250 million Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. However, the company must obtain U.S. Food and Drug Administration (FDA) approval for an improved potency assay before it can enroll patients in the efficacy phase of the study. Editas' shares could enjoy a bump when it jumps this hurdle. This stock, which remained volatile and traded within the range of $14.88â$26.54 in the past one-month time frame, witnessed a sharp increase yesterday. Global Genomic Medicine Market Future Trends And Forecast 2021 â 2027 | Emerging Players-Aevi Genomic Medicine, Inc., DEEP GENOMICS, Congenica Ltd., Editas Medicine Data Bridge Market Research March 18, 2021 editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. The reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.10. As such, we believe Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are poised to deliver solid returns based on their growing exposure and advancements in the healthcare race. Editas Medicine, Inc. EDIT was a big mover last session, as the company saw its shares rise 9% on the day. Outlook. Its quarterly revenue was up 13.6% compared to the same quarter last year. Date. The posted consensus target is $53.57, and the shares closed Thursday at â¦ Why Editas Medicine Stock Sank Today Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech. Editas Medicine, Inc. (EDIT) estimates and forecasts Editas Medicine Inc is a gene-editing company. This price target is based on 12 analysts offering 12 month price targets for Editas Medicine in the last 3 months. Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know. The Editas Medicine, Inc stock price gained 2.97% on the last trading day (Monday, 14th Jun 2021), rising from $37.42 to $38.53. According to analyst projections, EDITâs forecast low is $14 with $69 as the target high. Close price at the end of the last trading day (Friday, 4th Jun 2021) of the EDIT stock was $33.67. Latest Share Price and Events Stable Share Price : EDIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. EDIT - Solid growth stock within the biotech industry recently beat down, currently off 62% from the highs. Conference Call The Editas Medicine (EDIT) management team will host a conference call and webcast today at 8:00 a.m. Latest Share Price and Events Stable Share Price : EDIT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. See Editas Medicine, Inc. (EDIT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Get free access to Grant's best tips along with exclusive videos, never-released podcast episodes, wealth-building how-to's, time-saving calculators, mind-blowing courses, and way more. Following the recent earnings report, the consensus from seven analysts covering Editas Medicine is for revenues of US$22.2m in 2021, implying a concerning 32% decline in sales compared to the last 12 months. 87.52% of the stock of Editas Medicine is held by institutions. CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. â¦ It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The stock market forecast has been dimmed because a number of Democrat initiatives. CRISPR gene-editing stocks are being hit hard by a broader biotech sell-off on Tuesday. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 7587147. Editas Medicine Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.75 with sales reaching $5.78M over the same period.The EPS is expected to grow by 26.00% this year, but quarterly earnings will post  â¦ Monday, Jun 14, 2021. (AP) _ Editas Medicine Inc. (EDIT) on Wednesday reported a â¦ Get free access to Grant's best tips along with exclusive videos, never-released podcast episodes, wealth-building how-to's, time-saving calculators, mind-blowing courses, and way more. EDIT Stock Summary. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. 1: Adjusted price after possible price splits or reverse-splits. Estimated Average Forecasted BioNTech Price: 223.81 Positive intraday dynamics of the instrument is expected with 5.358% volatility is expected. After the option alert, the stock price moved up to $31.43. The company report on June 16, 2021 that Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer.. Get the hottest stocks to trade every day before the market opens 100% free. But Fed Meeting In The Forecast. The average price target represents a 18.28% increase from the last price of $35.51. BioNTech stock forecast for 17.06.2021. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 4 suggest the stock â¦ Pessimistic forecast: 220.59 Optimistic: 233.08 BioNTech stock forecast for 18.06.2021. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 shares of its common stock. Zooming out, Editas is on the forefront of pioneering a new class of breakthrough gene-edited medicines. The 7 Best Long Term Stocks to Buy in 2021 Stock Market for Beginners: An Overview Best Stock Trading Apps Let's stop the grind, together. The average price target is $47.36, with a high forecast of $86.00 and a low forecast of $14.00. The average price target is $42.00 with a high forecast of $75.00 and a low forecast of $20.00. 4 months ago - Zacks Investment Research. Analyst Price Target on EDIT. 5 Stocks To Watch For June 11, 2021 Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 Agree Realty Posts Q1 Earnings Beat, Raises â¦ ... 2021. Editas Medicine (NASDAQ:EDIT) stock had declined 13.7%, while Intellia Therapeutics (NASDAQ:NTLA) shares had slumped 11.4%. EDIT Stockâs Forward Dividend of 0 and its yield of 0% are making investorsâ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. There was no particular change to the consensus price target of US$44.38, with Editas Medicine's latest outlook seemingly not enough to result in a change of valuation. Editas Medicine, Inc. is expected* to report earnings on 02/25/2021 before market open. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 7587147. Editas Medicine (EDIT) stock price prediction is 64.431581 USD. The Editas Medicine stock forecast is 64.431581 USD for 2022 May 04, Wednesday; and 251.478 USD for 2026 May 04, Monday. Editas Medicine stock forecast, EDIT price prediction: Buy or sell Editas Medicine, Inc. shares? ";s:7:"keyword";s:26:"editas stock forecast 2021";s:5:"links";s:1186:"<a href="https://royalspatn.adamtech.vn/71p88/kirito-dual-wield-wallpaper">Kirito Dual Wield Wallpaper</a>,
<a href="https://royalspatn.adamtech.vn/71p88/used-cars-for-sale-queens-ny-craigslist">Used Cars For Sale Queens Ny Craigslist</a>,
<a href="https://royalspatn.adamtech.vn/71p88/capillary-puncture-finger">Capillary Puncture Finger</a>,
<a href="https://royalspatn.adamtech.vn/71p88/district-3-police-phone-number">District 3 Police Phone Number</a>,
<a href="https://royalspatn.adamtech.vn/71p88/windows-10-remove-password-and-pin">Windows 10 Remove Password And Pin</a>,
<a href="https://royalspatn.adamtech.vn/71p88/science-fiction-books-for-kids">Science Fiction Books For Kids</a>,
<a href="https://royalspatn.adamtech.vn/71p88/woocommerce-add-product-to-order-programmatically">Woocommerce Add Product To Order Programmatically</a>,
<a href="https://royalspatn.adamtech.vn/71p88/mba-moscow-u21-bc-enisey-krasnoyarsk-u21">Mba Moscow U21 Bc Enisey Krasnoyarsk U21</a>,
<a href="https://royalspatn.adamtech.vn/71p88/hokkaido-backcountry-club">Hokkaido Backcountry Club</a>,
<a href="https://royalspatn.adamtech.vn/71p88/salesforce-zimmer-biomet">Salesforce Zimmer Biomet</a>,
";s:7:"expired";i:-1;}